Related Experiment Video
Updated: Jun 24, 2025
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
6.2K
Prethrombin-1 as a Drug Substance Promoting Hemostasis with Reduced Risk of Thrombosis
Johann Georg Graus1, Michael Prückler2, Helga Bergmeister2
1Biomedizinische Forschung and Bio-Produkte AG, Vienna, Austria.
Thrombosis and Haemostasis
|June 12, 2024
Summary
Prethrombin-1 demonstrates effective hemostasis in animal models, promoting blood clotting with minimal thrombotic risk. This finding suggests its potential as a safe and life-saving treatment for bleeding disorders.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- Prethrombin-1 is an inactive prothrombin fragment lacking the Gla-domain.
- It arises from the cleavage of prothrombin by thrombin.
Purpose of the Study:
- To evaluate the hemostatic and thrombogenic properties of prethrombin-1.
- To compare prethrombin-1 with other prothrombin complex concentrates.
Main Methods:
- Hemostatic efficacy assessed in rabbit and mouse bleeding models (nail/tail clipping).
- Thrombogenic potential evaluated using a modified Wessler test in rabbits.
- Dose escalation studies conducted with comparisons to prothrombin, Beriplex®, FEIBA®, and saline.
Main Results:
- Prethrombin-1 exhibited significant hemostatic properties in anticoagulated animal models.
- Wessler tests indicated negligible thrombogenic potential for prethrombin-1 compared to prothrombin complexes.
Conclusions:
- Prethrombin-1 effectively promotes hemostasis with a reduced risk of thrombosis.
- Prethrombin-1 shows promise as a potential therapeutic agent for managing bleeding conditions.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
519
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
519
01:24Disorders of Hemostasis
837
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
837
01:16Clot Retraction and Fibrinolysis
5.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.5K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.1K